BeiGene (HKSE:06160) 6-Month Price Index : 1.24 (As of May. 03, 2025)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2025-05-03), BeiGene's 6-Month Price Index is 1.24.

Competitive Comparison of BeiGene's 6-Month Price Index

For the Biotechnology subindustry, BeiGene's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeiGene (HKSE:06160) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeiGene (HKSE:06160) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

BeiGene 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of BeiGene's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 49B:Germany 688235:China B1ME34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Oyler John Victor	2101 Beneficial owner
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines